Prescription costs for low-value treatments have reportedly risen in the U.K. despite a drop in prescription numbers, according to research published by the Journal of the Royal Society of Medicine.
NHS England reportedly identified low-value treatments which have been branded ineffective and too expensive, according to a EurekAlert! report.
Researchers from the Nuffield Department of Primary Care Health Science, University of Oxford, analyzed NHS’ data to determine how the low-priority treatments were used, how their use changed over time and prescription variations.
“There were almost one million fewer prescriptions for low-value items between July 2016 and June 2017, compared with the previous year,” lead researcher Ben Goldacre said. “Despite the consistent downward trend in items, costs have risen, increasing by 4.5 million euros when comparing 2016/17 with 2015/16.”
To read the full report on EurekAlert!, click here.